Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

(NasdaqGM:FOLD), PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss financial results for the quarter ended September 30, 2025. Participants and investors interested in accessing the call […]

Shoals Technologies Group, Inc. Announces Participation in Upcoming Events for the Investor Community

(NasdaqGM:SHLS), PORTLAND, Tenn., Oct. 23, 2025 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global leader in electrical balance of systems (“EBOS”) solutions for the energy transition market, announced today its participation in the following upcoming investor events: November 6, 2025: Bank of America Virtual Fireside ChatShoals' CFO, Dominic

Tecnoglass Sets Date for Third Quarter 2025 Results

(NYSE:TGLS), Miami, FL, Oct. 23, 2025 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced it will release financial results for the third quarter 2025 before the market opens on Thursday,

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

(NasdaqGM:LGND), JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and

HanchorBio’s Novel CD47-SIRPa Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology

— Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. — Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development

Stanley Steemer Supports Seasonal Wellness with Whole-Home UV Air Purification for Cleaner, Healthier Air

Dublin, OH, Oct. 23, 2025 (GLOBE NEWSWIRE) — As temperatures drop and families spend more time indoors, Stanley Steemer, the leader in professional deep home cleaning, is helping homeowners breathe easier with a Whole-Home UV Air Purification System. Installed directly within a home's HVAC system, the in-duct ultraviolet purifier uses advanced UV technology to neutralize

Announcing the 2025 Fortune Best Workplaces for Women

Oakland, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Great Place To Work(R) and Fortune have released the winners of the 2025 Fortune Best Workplaces for Women(TM) List. Great Place To Work analyzed survey responses from nearly 605,000 women who work for Great Place To Work Certified(TM) companies that were eligible for the list. To be

Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue(TM) protein degraders into clinical development

Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista's clinical development capabilities and accelerate its ambition to bring its innovative Targeted Glue(TM) protein degraders to patients Cambridge, UK, 23 October 2025 – Amphista Therapeutics, a leader in the discovery of next-generation, Targeted Protein Degradation

TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate

GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placebo Trial results were presented during a plenary session of the World Stroke Congress 2025 in Barcelona London, UK, Boston, MA, 23 October 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic

Marex Group Plc to Announce Third Quarter 2025 Earnings on November 6, 2025

(NASDAQ:MRX), NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) — Marex Group plc (NASDAQ: MRX) today announced that it will release its fiscal 2025 third quarter results before market open on Thursday, November 6, 2025. The earnings release and supplementary materials will be available through the “Investors” section of the Marex website at https://ir.marex.com/. A conference

Scroll to Top